科學技術-科研成就

專注提供質高價優

的生物藥

科學論文

Phase II study of pyrotinib plus albumin-bound paclitaxel and Trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer
ESMO 2024
Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: A randomized, double-blind,multicenter phase 3 study(ASTRUM-007).
ASCO 2023
First-line HLX07 Plus Serplulimab With or Without Chemotherapy Versus Serplulimab Plus Chemotherapy in Advanced/Recurrent Squamous Non-small Cell Lung Cancer: a Phase 2 study
ESMO Asia 2023
A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.
ASCO 2023
Safety and tolerability of HLX07combined with chemotherapy in patients with advanced solid tumors.
ASCO 2023
Luo F , Hao M , Zhang L ,et al.Identification of nonvolatile organic compounds (NVOCs) in biopharmaceuticals through non-target analysis and quantification using complexation-precipitation extraction[J].Journal of Chromatography A, 2024, 1713(000):10.DOI:10.1016/j.chroma.2023.464540.
Journal of Chromatography A

知識產權

專利申請數量	PCT申請數量	國內表授權專利數量	註冊司法權區	申請日期	到期日	發明專利數量
809	90	134	中國大陸	2011-03-18	2031-03-18	97

PG国际